Lynparza is a PARP inhibitor that was originally developed in the 1990s and is currently used to treat ovarian cancer.
Lynparza was developed by the pharmaceutical company AstraZeneca.
In 2020, results from a phase 3 clinical trial found that patients with advanced prostate cancer which has spread outside the prostate, and who have genetic variants in BRCA1, BRCA2 and ATM, lived longer and spent more time without their cancer getting worse when they took Lynparza.
To find out more about what genetic variants are click here.
The positive outcome of this clinical trial led to Lynparza being approved in the USA and the EU. It is currently being considered for approval in England.
To find out more about the typical timescales involved in developing new drugs and more information about clinical trials please click here.
You can find out more about Lynparza here.
If you are interested in hearing updates about Lynparza’s development journey please fill out your details below and we will be sure to update you when we have news. This information will not be used for any purpose other than providing you updates on Lynparza and will not be shared outside our organisation.